Loading stock data…
Unicycive Therapeutics, Inc. (UNCY)
N/A
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
Historical Price
No chart data available for UNCY
Whystock Brain
The Narrative
Unicycive Therapeutics, Inc. in the Healthcare sector is trading at $7.70 with a market capitalization of $192M. Wall Street consensus targets $41.30 (10 analysts), implying a +436.4% move over the next 12 months. The stock is currently 12% below its 52-week high of $8.74, remaining 23.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +436.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.44M↓ | -$7.22M↑ | -$7.34M↓ | -$6.96M↑ | -$7.99M |
| Net Income | -$12.82M↑ | -$14.67M↓ | -$6.01M↑ | -$6.45M↓ | $570,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate bindin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$192.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-105.95%
Volume
Today's trading volume
-
Recent News
Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?
Unicycive Therapeutics, Inc. recently reported first-quarter 2026 results showing a net loss of US$12.82 million, reversing net income of US$570,000 a year earlier and turning prior earnings per share from continuing operations into a loss. A few days before the earnings release, the company also filed a US$7.76 million common stock shelf registration tied to an employee stock ownership plan, signaling a focus on future equity-based compensation and potential capital access. With these...
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well
Key Insights Unicycive Therapeutics' significant retail investors ownership suggests that the key decisions are...
When Will Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Turn A Profit?
We feel now is a pretty good time to analyse Unicycive Therapeutics, Inc.'s ( NASDAQ:UNCY ) business as it appears the...
Is Unicycive Therapeutics (NASDAQ:UNCY) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...